ADCT - ADC Therapeutics SA

QQQ $ 602.61 $ 4.22 (0.71 %)

DIA $ 463.04 $ 0.00 (0 %)

SPY $ 665.11 $ 2.94 (0.44 %)

TLT $ 90.76 $ -0.20 (-0.22 %)

GLD $ 387.41 $ 6.60 (1.73 %)

Previous Close

$ 4.26

Open

$ 4.12

Bid

$ 4.00 x 300

Ask

$ 4.41 x 900

Day's Range

$ 4.10 - $ 4.37

52 Week Range

$ 1.05 - $ 4.74

Volume

1,046,389

Average Volume

Market Cap

479.25M

Beta (5Y Monthly)

$ 1.75

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-14-2025	03-31-2025	10-Q
3	03-27-2025	12-31-2024	10-K
4	11-07-2024	09-30-2024	10-Q
5	08-06-2024	06-30-2024	10-Q
6	05-06-2024	03-31-2024	10-Q
7	03-13-2024	12-31-2023	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

ADC Therapeutics Announces $60M Private Pl...
10/13/2025 11:35:49

12 Health Care Stocks Moving In Thursday's...
10/02/2025 21:06:15

Top 5 Biotech Stocks With Strong Momentum
08/28/2025 11:19:00

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

Guggenheim Reiterates Buy on ADC Therapeut...
08/13/2025 13:47:04

Guggenheim analyst Michael Schmidt reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $10 price target.

ADC Therapeutics Q2 Adj. EPS $(0.25) Beats...
08/12/2025 11:31:00

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.39...

Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

Preview: ADC Therapeutics's Earnings
08/11/2025 19:03:51

RBC Capital Maintains Outperform on ADC Th...
06/20/2025 13:55:48

RBC Capital analyst Leonid Timashev maintains ADC Therapeutics (NYSE:ADCT) with a Outperform and lowers the price target fro...

ADC Therapeutics To Present Updated Data F...
06/16/2025 11:17:07

Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response...

Guggenheim Maintains Buy on ADC Therapeuti...
06/13/2025 14:14:19

Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and raises the price target from $7 to ...

ADC Therapeutics Raises $100M in Private S...
06/12/2025 10:51:37

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), ...

ADC Therapeutics Reports 93% Response Rate...
06/12/2025 10:35:20

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), ...

RBC Capital Reiterates Outperform on ADC T...
05/15/2025 15:46:01

RBC Capital analyst Gregory Renza reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $8 price target.

ADC Therapeutics Q1 Adj. EPS $(0.22) Beats...
05/14/2025 12:04:24

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.40...

ADC Therapeutics Presents Data From LOTIS-...
05/14/2025 11:47:37

ZYNLONTA® plus glofitamab (COLUMVI®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refra...

Earnings Scheduled For May 14, 2025
05/14/2025 08:32:23

Preview: ADC Therapeutics's Earnings
05/13/2025 19:04:36

ADC Therapeutics' Claudin-6 Targeting ADC ...
04/28/2025 11:09:54

Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian a...

Guggenheim Maintains Buy on ADC Therapeuti...
03/31/2025 13:54:02

Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to...

HC Wainwright & Co. Reiterates Buy on ADC ...
03/31/2025 12:51:25

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $8 price target.